This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Biomarkers of Prednisolone Treatment (P05888)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00971724
First received: September 3, 2009
Last updated: May 21, 2015
Last verified: May 2015
  Purpose

Primary objective:

  • To identify a biomarker or biomarker-set for the adverse metabolic effects of various doses of prednisolone treatment.

Secondary objectives:

  • To describe the PK of prednisolone and PD of a series of biomarkers.
  • To identify biomarkers that reflect side effects of prednisolone.
  • To elucidate part of the mechanisms by which prednisolone induces metabolic changes.

Condition Intervention
Insulin Resistance Hyperglycemia Glucose Intolerance Drug: Placebo Drug: Prednisolone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Single-center Study Using Multiple Doses of Prednisolone to Quantify Effects on Selected Biomarkers and Assess Pharmacokinetics in Healthy Males

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • To identify a biomarker or biomarker-set for adverse metabolic effects of various doses of prednisolone [ Time Frame: Day 1 and day 15 ]

Secondary Outcome Measures:
  • To describe the PK of prednisolone and PD of a series of biomarkers [ Time Frame: Day 1 and day 15 ]

Enrollment: 72
Study Start Date: May 2006
Study Completion Date: March 2008
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Treatment with placebo for 15 days
Drug: Placebo
Oral administration, once daily, for 15 days
Experimental: Prednisolone 7.5 mg daily
Treatment with prednisolone 7.5 mg daily for 15 days
Drug: Prednisolone
Oral administration
Experimental: Prednisolone 15 mg daily
Treatment with prednisolone 15 mg daily for 15 days
Drug: Prednisolone
Oral administration
Experimental: Prednisolone 30 mg daily
Treatment with prednisolone 30 mg daily for 15 days
Drug: Prednisolone
Oral administration
Experimental: Prednisolone 75 mg
Treatment with prednisolone 75 mg for a single day
Drug: Prednisolone
Oral administration
Experimental: Prednisolone 15 mg twice daily
Treatment with prednisolone 15 mg twice daily for a single day
Drug: Prednisolone
Oral administration

  Eligibility

Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 22 < BMI < 30
  • fasting glucose < 5.6 mmol/L and glucose < 7.8 mmol/L 2hr after OGTT
  • able and willing to sign informed consent
  • history of good physical and mental health
  • subject smokes less than 5 cigarettes per day
  • able to keep a normal day and night rhythm

Exclusion Criteria:

  • allergy to prednisolone
  • glucocorticoid use during last 3 months prior to study
  • use of any drug or substance
  • history of familiar diabetes type 2
  • clinically relevant history or presence of any medical disorder
  • clinically relevant abnormal lab or ECG
  • positive drug or alcohol screen, positive hepatitis B or C surface antigen
  • donation of blood (>100 mL) within 90 days prior to the first dose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00971724     History of Changes
Other Study ID Numbers: P05888
294001 ( Other Identifier: Merck )
Study First Received: September 3, 2009
Last Updated: May 21, 2015

Keywords provided by Merck Sharp & Dohme Corp.:
Prednisolone
Glucocorticoids

Additional relevant MeSH terms:
Insulin Resistance
Hyperglycemia
Glucose Intolerance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Prednisolone acetate
Methylprednisolone acetate
Prednisolone
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents

ClinicalTrials.gov processed this record on June 21, 2017